AzTrials
AzTrials

Ventricular Drain Related InfectionEVD Infect IINCT05904535

Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections

An observational study of Ventricular Drain Related Infection and Nosocomial Infection, run by Karolinska University Hospital at 1 site in Sweden.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

External ventricular drain infections are difficult to identify with current diagnostic methods. Initiation of antibiotic treatment is usually supported by indirect methods of bacterial infection, such as clinical signs or cerebrospinal fluid cell counts (CSF). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Cerbrospinal fluid sampling.
How many people
100 participants
Where
1 siteSweden
Study dates
21 Sep 2022to 31 Dec 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients with a minimum age of 18, who are admitted to the ICU and treated with an external ventricular drain. All patients will be included regardless of underlying admission diagnosis.

Who may be able to join

  • Treated with an external ventricular drain.
  • Admitted to the neurocritical and critical care unit at Karolinska University Hospital in Solna, Sweden.

Who cannot join

  • 1. Does not fulfill age requirements.

Trial locations and contacts

1 site in 1 country.

David W Nelson, MD, PhD contact

0851779168 ext. +46

david.nelson@ki.se

Marcus Bådholm, MD contact

0707761402 ext. +46

marcus.badholm@ki.se

Sweden1 site, 1 recruiting
  • Perioperative Medicine and Intensive Care, Karolinska University Hospital

    Stockholm, 17176

    David W Nelson, MD, PhD, 0851779168 ext. +46, david.nelson@regionstockholm.se.se

    Recruiting

Other trials in Sweden

About this study

External ventricular drain infections are difficult to identify with current diagnostic methods. Initiation of antibiotic treatment is usually supported by indirect methods of bacterial infection, such as clinical signs or cerebrospinal fluid cell counts (CSF). As such, excessive treatment with antibiotics is common in these patients due to suspected infection while the incidence of true culture confirmed infections are less common. This study will evaluate three novel diagnostic methods for rapid direct bacterial detection in CSF, in order to assess if these can be used to guide antibiotic treatment in neurocritically ill patients, compared to CSF bacterial cultures.

Read the detailed description

In the literature, the reported incidence ranges between 1-35% of inserted drains. This disparity results from the lack of an international consensus on a definition for EVDIs and the use of various diagnostic criteria across studies. In a neurointensive care setting, clinical symptoms are often difficult to evaluate due to underlying illness. Cerebrospinal fluid (CSF) bacterial culture is the current golden standard of EVDI diagnostics. However, CSF bacterial cultures often take several days to finalize and prior use of antibiotics may further prolong culture incubation time or cause false negative cultures. It is seldom possible to delay treatment until the bacterial cultures have finalized. Additionally, due to the etiology of these infections, contamination and true positives can be difficult to distinguish based on the cultured bacteria alone. Thus, early identification of EVDIs are based on indirect signs of bacterial infection, namely CSF analysis of glucose, lactate, protein, leukocytes, and erythrocytes. In the neurocritically ill, CSF parameters are frequently confounded by intraventricular hemorrhage (IVH). Leukocytes and erythrocytes in particular may vary greatly depending on the IVH volume.

To adjust for IVH, the ratio of leukocytes and erythrocytes (LE ratio) in CSF is commonly used and is one of the main metrics in identifying EVDIs. The LE ratio is based on the assumption that erythrocytes and leukocytes are homogeneously distributed in the CSF. This assumption has previously not been questioned. However, it is clear from computed tomography (CT) scans that blood sediments in the ventricles, suggesting that a homogeneous distribution is unlikely. The LE ratio fails to account for the fact that the blood causes an aseptic inflammation in itself, resulting in immigration of leukocytes. Additionally, leukocytes, in particular granulocytes, may exhibit upwards floatation, or antisedimentation, a property shown to be exacerbated in critically ill patients. Thus, leukocytes may sediment at a slower rate than erythrocytes which may further skew the intraventricular CSF/blood distribution towards heterogeneity.

Due to the specific pathogens, patient characteristics, and confounding factors, early identification of EVDIs have proven difficult and no CSF parameter, by itself or in aggregate, have yet been shown to reliably predict or identify EVDIs. As such, algorithms based on routinely analyzed CSF parameters and clinical symptoms are ambiguous and diagnosis is often based on "expert-opinion". This results in an excessive use of broad spectrum antibiotics and a large variation in clinical practice, with up to 10-20 patients being treated for every true infection. Additionally, the main metric in EVDI diagnostics, the LE ratio, is based on the uncertain assumption that cells are homogeneously distributed in the CSF. If, and how, this affects routinely analyzed CSF parameters has yet to be studied. With the questionable precision of current indirect methods to identify EVDIs in mind, there is a need for more rapid and accurate tools for direct microbiological detection and identification in the diagnostics of EVDI.

The use of emerging bacterial DNA sequencing techniques in infectious diseases medicine increasing. Unfortunately, these techniques for CSF with primers covering the specific bacteria found in EVDIs have not yet been verified. Moreover, due to the lack of established around the clock work flows surrounding these methods, results from these techniques are not yet readily available within the time-frame needed to decide whether to instigate treatment. However, regular PCR methods have been shown to identify bacteria in a large portion of clinically suspected severe sepsis patients exhibiting negative blood cultures. Interestingly, this group had the highest mortality suggesting that the positive bacterial findings were not just due to the use of an oversensitive technique. Bacterial DNA sequencing techniques may have the potential to exhibit a higher sensitivity compared to conventional bacterial cultures within a smaller time frame.

16s ribosomal ribonucleic acid (16s rRNA) is a component of the prokaryotic ribosomal 30s subunit and is present in all prokaryotic lifeforms. The use of 16s rRNA sequencing have been shown to reliably identify bacteria in normally sterile body fluids, such as CSF, compared to bacterial cultures. 16s rRNA also have the advantage of being able to identify non viable bacteria, thus potentially exhibiting a greater sensitivity in patients who have been subjected to antibiotic treatment prior to sampling, making it a promising target for bacterial DNA sequencing. However, 16s rRNA sequencing have not been studied extensively for EVDIs.

Optotracing is a novel method for identification of bacteria and bacterial biofilms. The method is based on luminescent conjugated oligothiophenes (LCOs), a polymer which exhibit optoelectric properties. Interaction between LCOs and biofilm products or bacteria directly lead to target specific fluorescent emission which allows for optical detection. The method have recently been found to reliably identify biofilm producing uropathogenic E. Coli in patients with urinary tract infection. Furthermore, the method was able to differentiate between healthy and infected urine regardless of the detection of biofilm products. Optoelectric polymers are versatile molecules enabling easy modification which may allow for tailored target specific interaction, potentially allowing optotracing to be used as a method for specific rapid bacterial identification in EVDI diagnostics.

In addition to optotracing, electrochemical sensing of bacterial metabolic activity (REDOX) have recently been investigated as a new method of bacterial detection. REDOX exploits the reducing capabilities of bacteria. This property have enabled the creation of a rapid, highly sensitive test array using polymers with semiconductive properties acting as an electron acceptor. This method allows for the measurement of the metabolic activity of bacteria in real-time by measuring the current induced by direct transfer of electrons from the bacteria to the polymer surface or indirectly, by release of redox active compounds. The use of conducting and optoeletric polymers to detect bacteria represents an exiting new field of research with promising clinical applications that may enable direct, precise, and rapid microbiological diagnostics and allow for real-time surveillance of bacterial growth.

The overall aim of this project is to study novel methods of direct bacterial detection in EVDI diagnostics to evaluate if these methods can be used to guide treatment in order to reduce excessive treatment with broad-spectrum antibiotics in neurocritically ill patients.

Being tested
Cerbrospinal fluid sampling.
Medical subject headings
Cross Infection, Bacterial Infections, Cerebral Ventriculitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cerbrospinal fluid sampling.Other

    Routine sampling of cerebrospinal fluid from the proximal external ventricular drain port.

Study groups in NCT05904535
Study groupRoleWhat they receive
All patientsCerebrospinal fluid will be collected from all study subjects and analyzed with sequencing techniques, Optotracing, and REDOX. All methods will compared with CSF bacterial cultures which is the current golden standard.
Receives: Other: Cerbrospinal fluid sampling.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Specificity

    Each methods specificity will be prospectively evaluated.

    Measured: 2022-2025

Secondary outcomes (1)
  1. Sensitivity

    Each methods sensitivity will be prospectively evaluated. Due to the low incidence of true infections the sensitivity will mainly be evaluated using spiked CSF samples.

    Measured: 2022-2025

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Jun 2023
  2. Study start21 Sep 2022
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05904535
Sponsor's protocol ID
K 2022-7809
Acronym
EVD Infect II
Status last verified
Jun 2023
First submitted
6 Jun 2023
Last updated
15 Jun 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Anonymized data will be shared upon reasonable request.

Questions about this trial

What is this clinical trial studying?

An observational study of Ventricular Drain Related Infection and Nosocomial Infection, run by Karolinska University Hospital at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact David W Nelson, MD, PhD (0851779168 ext. +46, david.nelson@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Specificity (time frame: 2022-2025). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in